LONDON – Neogenomics Laboratories Inc. is to make a $25 million equity investment in Inivata Ltd. and has taken an option to acquire all of the company as part of a U.S. commercialization agreement with the U.K. liquid biopsy specialist. Under the deal, Neogenomics will take over sales, marketing and billing for Inivata’s Invisionfirst circulating tumor DNA lung cancer test, which is intended to replace tissue biopsies.
In a deal potentially worth $3 billion, privately held Repare Therapeutics Inc., of Cambridge, Mass., and Montreal, entered a research collaboration with Bristol Myers Squibb Co. (BMS) to identify synthetic lethal precision oncology targets for drug candidates.
SUZHOU, China – Genome editing startup Edigene Inc. and CAR T developer Immunochina Pharmaceuticals Co. Ltd., both from Beijing, have unveiled joint efforts to develop an allogeneic CAR T therapy for cancer. Terms remain undisclosed.
Arcus Biosciences Inc. “brings the milk without [Gilead Sciences Inc.] having to buy the whole cow” is the way one analyst characterized the pair’s 10-year cancer immunotherapy deal, which could be worth as much as $2 billion, and some may have detected downside for Arcus, as shares (NYSE:RCUS) closed May 27 at $27.05, down $6.49, or 19%. Foster City, Calif.-based Gilead is paying Arcus, of Hayward, Calif., $175 million up front, shelling out a $200 million equity investment, and pledging potentially $1.6 billion or more in the form of R&D support, opt-in cash and milestone payments.
PERTH, Australia – Melbourne-based Prescient Therapeutics Pty Ltd. is poised to develop next-generation CAR T therapies after signing an exclusive global licensing deal with the University of Pennsylvania for a universal immune receptor technology platform.
Pharma and diagnostics giant Roche Holding AG, of Basel, Switzerland, has acquired Seattle-based Stratos Genomics Inc., an early-stage sequencing technology company, in a move aimed at advancing development of Roche’s nanopore sequencer. Financial terms of the deal, which was first reported on Friday, were not disclosed.
HONG KONG – France’s Sanofi SA has informed Hanmi Pharmaceuticals Co. Ltd. of its intention to return all the rights to efpeglenatide, the South Korean company’s diabetes drug candidate.
DUBLIN – Affibody AB is getting $10 million up front and up to $215.5 million in regulatory and sales milestones from a licensing deal with Inmagene Biopharmaceuticals Co. Ltd., in which the latter firm gains commercial rights to its interleukin-17 inhibitor ABY-035 in China, Hong Kong, Taiwan, Macau and South Korea.
Vividion Therapeutics Inc. has continued to build its roster of partnerships with a multitarget collaboration deal with Roche Holding AG that could be worth billions.
RSS
